326 related articles for article (PubMed ID: 26526839)
1. The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity.
Reis-Mendes AF; Sousa E; de Lourdes Bastos M; Costa VM
Curr Drug Metab; 2015; 17(1):75-90. PubMed ID: 26526839
[TBL] [Abstract][Full Text] [Related]
2. The importance of drug metabolites synthesis: the case-study of cardiotoxic anticancer drugs.
Hrynchak I; Sousa E; Pinto M; Costa VM
Drug Metab Rev; 2017 May; 49(2):158-196. PubMed ID: 28393622
[TBL] [Abstract][Full Text] [Related]
3. Anthracycline cardiotoxicity.
Menna P; Paz OG; Chello M; Covino E; Salvatorelli E; Minotti G
Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S21-36. PubMed ID: 21635149
[TBL] [Abstract][Full Text] [Related]
4. Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy.
Raschi E; Vasina V; Ursino MG; Boriani G; Martoni A; De Ponti F
Pharmacol Ther; 2010 Feb; 125(2):196-218. PubMed ID: 19874849
[TBL] [Abstract][Full Text] [Related]
5. Cardiotoxicity of cyclophosphamide's metabolites: an in vitro metabolomics approach in AC16 human cardiomyocytes.
Dionísio F; Araújo AM; Duarte-Araújo M; Bastos ML; Guedes de Pinho P; Carvalho F; Costa VM
Arch Toxicol; 2022 Feb; 96(2):653-671. PubMed ID: 35088106
[TBL] [Abstract][Full Text] [Related]
6. Naphthoquinoxaline metabolite of mitoxantrone is less cardiotoxic than the parent compound and it can be a more cardiosafe drug in anticancer therapy.
Reis-Mendes A; Gomes AS; Carvalho RA; Carvalho F; Remião F; Pinto M; Bastos ML; Sousa E; Costa VM
Arch Toxicol; 2017 Apr; 91(4):1871-1890. PubMed ID: 27629428
[TBL] [Abstract][Full Text] [Related]
7. Cardioncology: state of the heart.
Todaro MC; Oreto L; Qamar R; Paterick TE; Carerj S; Khandheria BK
Int J Cardiol; 2013 Sep; 168(2):680-7. PubMed ID: 23639459
[TBL] [Abstract][Full Text] [Related]
8. Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management.
Layoun ME; Wickramasinghe CD; Peralta MV; Yang EH
Curr Oncol Rep; 2016 Jun; 18(6):35. PubMed ID: 27113369
[TBL] [Abstract][Full Text] [Related]
9. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.
Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM
CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165
[TBL] [Abstract][Full Text] [Related]
10. [The cardiac toxicity of cancer chemotherapy].
Sequeira JF; Madruga IM; Ribeiro M; Duarte PC; Ferreira DC; Sarmento JL
Acta Med Port; 1994 May; 7(5):311-8. PubMed ID: 8073908
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond.
Moudgil R; Yeh ET
Can J Cardiol; 2016 Jul; 32(7):863-870.e5. PubMed ID: 27117975
[TBL] [Abstract][Full Text] [Related]
12. Curing Cancer, Saving the Heart: A Challenge That Cardioncology Should Not Miss.
Cardinale D; Biasillo G; Cipolla CM
Curr Cardiol Rep; 2016 Jun; 18(6):51. PubMed ID: 27108361
[TBL] [Abstract][Full Text] [Related]
13. Cardiotoxicity of cancer chemotherapy: implications for children.
Simbre VC; Duffy SA; Dadlani GH; Miller TL; Lipshultz SE
Paediatr Drugs; 2005; 7(3):187-202. PubMed ID: 15977964
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-induced cardiotoxicity: detection, prevention, and management.
Truong J; Yan AT; Cramarossa G; Chan KK
Can J Cardiol; 2014 Aug; 30(8):869-78. PubMed ID: 25064580
[TBL] [Abstract][Full Text] [Related]
15. An update on the risk prediction and prevention of anticancer therapy-induced cardiotoxicity.
Bhave M; Shah AN; Akhter N; Rosen ST
Curr Opin Oncol; 2014 Nov; 26(6):590-9. PubMed ID: 25233068
[TBL] [Abstract][Full Text] [Related]
16. The role of metabolic diseases in cardiotoxicity associated with cancer therapy: What we know, what we would know.
L'Abbate S; Russo I; Kusmic C
Life Sci; 2020 Aug; 255():117843. PubMed ID: 32464123
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-induced cardiotoxicity: new insights into mechanisms, monitoring, and prevention.
Cadeddu Dessalvi C; Deidda M; Mele D; Bassareo PP; Esposito R; Santoro C; Lembo M; Galderisi M; Mercuro G
J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):315-323. PubMed ID: 29708912
[TBL] [Abstract][Full Text] [Related]
18. A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
Spallarossa P; Maurea N; Cadeddu C; Madonna R; Mele D; Monte I; Novo G; Pagliaro P; Pepe A; Tocchetti CG; Zito C; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1(Suppl 1):S84-92. PubMed ID: 27183529
[TBL] [Abstract][Full Text] [Related]
19. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
Pai VB; Nahata MC
Drug Saf; 2000 Apr; 22(4):263-302. PubMed ID: 10789823
[TBL] [Abstract][Full Text] [Related]
20. Prevention and management of cardiotoxicity from antineoplastic therapy.
Chanan-Khan A; Srinivasan S; Czuczman MS
J Support Oncol; 2004; 2(3):251-6; discussion 259-61, 264-6. PubMed ID: 15328825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
